Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19
Standard
Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19. / Karagiannidis, Christian; Hentschker, Corinna; Westhoff, Michael; Weber-Carstens, Steffen; Janssens, Uwe; Kluge, Stefan; Pfeifer, Michael; Spies, Claudia; Welte, Tobias; Rossaint, Rolf; Mostert, Carina; Windisch, Wolfram.
in: PLOS ONE, Jahrgang 17, Nr. 1, e0262315, 2022.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19
AU - Karagiannidis, Christian
AU - Hentschker, Corinna
AU - Westhoff, Michael
AU - Weber-Carstens, Steffen
AU - Janssens, Uwe
AU - Kluge, Stefan
AU - Pfeifer, Michael
AU - Spies, Claudia
AU - Welte, Tobias
AU - Rossaint, Rolf
AU - Mostert, Carina
AU - Windisch, Wolfram
PY - 2022
Y1 - 2022
N2 - BACKGROUND: The role of non-invasive ventilation (NIV) in severe COVID-19 remains a matter of debate. Therefore, the utilization and outcome of NIV in COVID-19 in an unbiased cohort was determined.AIM: The aim was to provide a detailed account of hospitalized COVID-19 patients requiring non-invasive ventilation during their hospital stay. Furthermore, differences of patients treated with NIV between the first and second wave are explored.METHODS: Confirmed COVID-19 cases of claims data of the Local Health Care Funds with non-invasive and/or invasive mechanical ventilation (MV) in the spring and autumn pandemic period in 2020 were comparable analysed.RESULTS: Nationwide cohort of 17.023 cases (median/IQR age 71/61-80 years, 64% male) 7235 (42.5%) patients primarily received IMV without NIV, 4469 (26.3%) patients received NIV without subsequent intubation, and 3472 (20.4%) patients had NIV failure (NIV-F), defined by subsequent endotracheal intubation. The proportion of patients who received invasive MV decreased from 75% to 37% during the second period. Accordingly, the proportion of patients with NIV exclusively increased from 9% to 30%, and those failing NIV increased from 9% to 23%. Median length of hospital stay decreased from 26 to 21 days, and duration of MV decreased from 11.9 to 7.3 days. The NIV failure rate decreased from 49% to 43%. Overall mortality increased from 51% versus 54%. Mortality was 44% with NIV-only, 54% with IMV and 66% with NIV-F with mortality rates steadily increasing from 62% in early NIV-F (day 1) to 72% in late NIV-F (>4 days).CONCLUSIONS: Utilization of NIV rapidly increased during the autumn period, which was associated with a reduced duration of MV, but not with overall mortality. High NIV-F rates are associated with increased mortality, particularly in late NIV-F.
AB - BACKGROUND: The role of non-invasive ventilation (NIV) in severe COVID-19 remains a matter of debate. Therefore, the utilization and outcome of NIV in COVID-19 in an unbiased cohort was determined.AIM: The aim was to provide a detailed account of hospitalized COVID-19 patients requiring non-invasive ventilation during their hospital stay. Furthermore, differences of patients treated with NIV between the first and second wave are explored.METHODS: Confirmed COVID-19 cases of claims data of the Local Health Care Funds with non-invasive and/or invasive mechanical ventilation (MV) in the spring and autumn pandemic period in 2020 were comparable analysed.RESULTS: Nationwide cohort of 17.023 cases (median/IQR age 71/61-80 years, 64% male) 7235 (42.5%) patients primarily received IMV without NIV, 4469 (26.3%) patients received NIV without subsequent intubation, and 3472 (20.4%) patients had NIV failure (NIV-F), defined by subsequent endotracheal intubation. The proportion of patients who received invasive MV decreased from 75% to 37% during the second period. Accordingly, the proportion of patients with NIV exclusively increased from 9% to 30%, and those failing NIV increased from 9% to 23%. Median length of hospital stay decreased from 26 to 21 days, and duration of MV decreased from 11.9 to 7.3 days. The NIV failure rate decreased from 49% to 43%. Overall mortality increased from 51% versus 54%. Mortality was 44% with NIV-only, 54% with IMV and 66% with NIV-F with mortality rates steadily increasing from 62% in early NIV-F (day 1) to 72% in late NIV-F (>4 days).CONCLUSIONS: Utilization of NIV rapidly increased during the autumn period, which was associated with a reduced duration of MV, but not with overall mortality. High NIV-F rates are associated with increased mortality, particularly in late NIV-F.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - COVID-19/epidemiology
KW - Female
KW - Hospital Mortality
KW - Humans
KW - Intubation, Intratracheal/statistics & numerical data
KW - Length of Stay
KW - Male
KW - Middle Aged
KW - Noninvasive Ventilation/statistics & numerical data
KW - Respiration, Artificial/statistics & numerical data
KW - Treatment Outcome
KW - Young Adult
U2 - 10.1371/journal.pone.0262315
DO - 10.1371/journal.pone.0262315
M3 - SCORING: Journal article
C2 - 35030205
VL - 17
JO - PLOS ONE
JF - PLOS ONE
SN - 1932-6203
IS - 1
M1 - e0262315
ER -